Aarey Drugs & Pharmaceuticals Intrinsic Value
Aarey Drugs & Pharmaceuticals intrinsic value. Aarey Drugs & Pharmaceuticals (AAREYDRUGS) median intrinsic value is ₹44.83 from 8 valuation models (range ₹32–₹216), vs current price ₹107.85 — -58.4% downside (Trading Above Calculated Value), margin of safety -100.0%. Compare with AAREYDRUGS fundamental valuation to assess whether the stock is under or overvalued.
AAREYDRUGS Valuation Methods Summary — DCF, Graham Number & P/E
Aarey Drugs & Pharmaceuticals intrinsic value across 8 models vs current price ₹107.85 — upside/downside and value range per method. For current market price and key ratios, visit AAREYDRUGS screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹33.00 | ₹26.40 - ₹39.60 | -69.4% | EPS: ₹1.50, Sector P/E: 22x |
| Book Value Method | asset | ₹95.86 | ₹86.27 - ₹105.45 | -11.1% | Book Value/Share: ₹47.93, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹215.70 | ₹194.13 - ₹237.27 | +100.0% | Revenue/Share: ₹145.17, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹44.83 | ₹40.35 - ₹49.31 | -58.4% | EBITDA: ₹13.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹46.84 | ₹37.47 - ₹56.21 | -56.6% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹32.35 | ₹29.12 - ₹35.59 | -70.0% | EPS Growth: 0.2%, Fair P/E: 0.1x |
| Growth Adjusted P/E | growth | ₹32.35 | ₹29.12 - ₹35.59 | -70.0% | Revenue Growth: -0.1%, Adj P/E: 15.0x |
| Graham Defensive Method | conservative | ₹40.22 | ₹36.20 - ₹44.24 | -62.7% | EPS: ₹1.50, BVPS: ₹47.93 |
AAREYDRUGS Intrinsic Value vs Market Price — All Valuation Models
Aarey Drugs & Pharmaceuticals fair value range ₹32–₹216 vs current market price ₹107.85 across 8 valuation models. Read AAREYDRUGS dividend history for the complete payout history and dividend yield track record.
AAREYDRUGS Intrinsic Value Analysis — Undervalued or Overvalued?
Aarey Drugs & Pharmaceuticals median intrinsic value ₹44.83, current price ₹107.85 — Trading Above Calculated Value by 58.4%, margin of safety -100.0%.
What is the intrinsic value of AAREYDRUGS?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Aarey Drugs & Pharmaceuticals (AAREYDRUGS) is ₹44.83 (median value). With the current market price of ₹107.85, this represents a -58.4% variance from our estimated fair value.
The valuation range spans from ₹32.35 to ₹215.70, indicating ₹32.35 - ₹215.70.
Is AAREYDRUGS undervalued or overvalued?
Based on our multi-method analysis, Aarey Drugs & Pharmaceuticals (AAREYDRUGS) appears to be trading above calculated value by approximately 58.4%.
AAREYDRUGS Financial Health — Key Ratios vs Industry Benchmarks
Aarey Drugs & Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 88.67 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 2.9% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 2.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.45x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
AAREYDRUGS Cash Flow Quality — Operating & Free Cash Flow
Aarey Drugs & Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹10 Cr | ₹7 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹-3 Cr | ₹-4 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-1 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹1 Cr | ₹-1 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹6 Cr | ₹5 Cr | Positive Free Cash Flow | 8/10 |